B of A Securities raises ACADIA price target to $30

0 min read     Updated on 01 Jul 2026, 01:14 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

B of A Securities analyst Tazeen Ahmad maintained a Buy rating on ACADIA Pharmaceuticals and raised the price target to $30 from $29.

powered bylight_fuzz_icon
44394248

*this image is generated using AI for illustrative purposes only.

B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on ACADIA Pharmaceuticals, raising the price target to $30 from $29. The adjustment reflects an updated outlook on the NASDAQ-listed stock.

Rating and Price Target Details

The revised price target of $30 represents an increase from the previous target of $29. The Buy rating was maintained, indicating continued confidence in the company's performance.

Metric Value
Rating Buy
Previous Price Target $29
New Price Target $30

What specific factors drove the modest increase in ACADIA's price target?

How might ACADIA's upcoming product pipeline influence its stock performance?

What are the potential risks to ACADIA's growth trajectory in the current market?

like15
dislike

Citigroup raises ACADIA price target to $35

0 min read     Updated on 29 Jun 2026, 09:27 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Citigroup maintained a Buy rating on ACADIA Pharmaceuticals and increased the price target to $35 from $32, reflecting an updated valuation outlook.

powered bylight_fuzz_icon
44292290

*this image is generated using AI for illustrative purposes only.

Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on ACADIA Pharmaceuticals and raised the price target to $35 from the previous $32. The adjustment reflects an updated valuation outlook for the NASDAQ-listed company.

Rating and Target Details

The research note reinforces a positive stance on the stock, citing the revised price target as a key indicator of potential upside. The table below summarizes the changes:

Metric Previous Value New Value
Rating Buy Buy
Price Target $32 $35

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol ACAD.

What specific factors drove the upward revision in ACADIA's valuation outlook?

How might ACADIA's recent clinical trial results influence future analyst ratings?

What are the potential market reactions if ACADIA meets or exceeds the new $35 price target?

like20
dislike

More News on ACADIA Pharmaceuticals Inc

Must Read Next

Earnings

Corporate Actions

Stocks